media – Page 4 – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

CanSino’s inhaled tuberculosis vaccine approved for clinical trials in Indonesia

May 15, CanSino(688185/06185) announced that the company’s inhaled tuberculosis vaccine (adenovirus type 5 vector) has recently obtained clinical trial approval from the Indonesian Food and Drug Administration. The development of this vaccine aims to solve the problem of BCG’s weakening protection over time and provide more effective immune protection. According to the World Health Organization, there will be 10.8 million new tuberculosis patients worldwide in 2023, showing the continued threat of tuberculosis, especially in Southeast Asia and Africa. This Phase I clinical trial will explore the safety and immunogenicity of the vaccine in adults aged 18-49. In the first quarter of 2025, CanSino Biologics achieved revenue of 137 million yuan and a net profit attributable to shareholders of the parent company of -11.55 million yuan. https://finance.eastmoney.com/a/202505153405639359.html
- Source: drugdu
- 49
- May 19, 2025
Xinghao Pharmaceutical’s Docetaxel Injection Receives FDA Approval of Abbreviated New Drug Application (ANDA)

On May 15, Xinghao Pharmaceutical announced that Guangdong Xinghao Pharmaceutical Co., Ltd. recently obtained approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for docetaxel injection. This approval qualifies the company to sell the drug in the U.S. market, marking an important step for the company in expanding overseas markets. Docetaxel injection is indicated for the treatment of breast cancer, non-small cell lung cancer, prostate cancer, gastric cancer and head and neck cancer. The dosage form is injection with specifications of 80mg/4mL and 20mg/1mL. In the first quarter of 2025, Xinghao Pharmaceutical achieved revenue of 142 million yuan and net profit attributable to shareholders of the parent company of 25.03 million yuan. https://finance.eastmoney.com/a/202505153405776677.html
- Source: drugdu
- 44
- May 19, 2025
North China Pharmaceutical’s subsidiary’s recombinant tetanus vaccine approved for clinical trials

On May 15, North China Pharmaceutical(600812) announced that its subsidiary Jintan Company recently received the “Drug Clinical Trial Approval Notice” for the recombinant tetanus vaccine (Escherichia coli) approved and issued by the National Medical Products Administration. The acceptance number of the notice is CXSL2500168, the notice number is 2025LP01313, the dosage form is injection, the specification is 30μg/0.5ml/piece, and the approval conclusion shows that the vaccine meets the relevant requirements for drug registration and agrees to conduct clinical trials. As of April 2025, Jintan’s cumulative R&D expenses for this drug are RMB 39.71 million (unaudited). Currently, there is no recombinant tetanus vaccine based on genetic engineering on the market at home and abroad, and Jintan’s R&D will fill this market gap. In the first quarter of 2025, North China Pharmaceutical achieved revenue of 2.574 billion yuan and net profit attributable to shareholders of the parent company of 57.49 million yuan. ...
- Source: drugdu
- 47
- May 19, 2025
The National Medical Products Administration approved the marketing of velaglucerase beta for injection

On May 15, the National Medical Products Administration approved the marketing of velaglucerase beta for injection (trade name: Gorenin) applied by Beihai Kangcheng (Shanghai) Biotechnology Co., Ltd. through the priority review and approval procedure. It is suitable for long-term enzyme replacement therapy for adolescents and adults with type I and type III Gaucher disease aged 12 and above. Gaucher disease is an autosomal recessive metabolic disease caused by functional defects of glucocerebrosidase in lysosomes and is included in the “First List of Rare Diseases”. Velaglucerase beta for injection can reduce the storage of glucocerebroside in the body, thereby exerting a therapeutic effect. The listing of this variety provides a new treatment option for related patients. 网址：https://finance.eastmoney.com/a/202505153405858055.html
- Source: drugdu
- 45
- May 19, 2025
China and the United States reduce their reciprocal tariffs to 10%

From May 10 to 11, high-level economic and trade talks between China and the United States were held in Geneva, Switzerland. After the talks, the two sides issued a joint statement today (May 12). The main contents are as follows: The Chinese chief negotiator for China-US economic and trade relations, Vice Premier He Lifeng, and the US chief negotiators, US Treasury Secretary Jeff Bessant and Trade Representative Greer, and other representatives of their respective governments, had candid, in-depth and constructive communication on the implementation of the important consensus reached in the phone call between the Chinese and US heads of state on January 17, and the talks made substantial progress. The United States will (i) modify the additional ad valorem tariffs on Chinese goods (including goods from the Hong Kong Special Administrative Region and the Macao Special Administrative Region) imposed by Executive Order No. 14257 of April 2, 2025, by ...
- Source: drugdu
- 39
- May 19, 2025
InnoCare Pharma holds 7.8 billion

On May 13, InnoCare Pharma released its first quarter 2025 performance report, which opened with a striking cash and related account balance of 7.78 billion yuan. This figure not only lays a solid foundation for the company’s current development, but also paves a broad road for its future strategic layout. InnoCare Pharma’s performance in the first quarter was also outstanding. The company’s revenue increased by 129.9% year-on-year to 380 million yuan, and it successfully achieved a net profit of 14 million yuan, reversing the loss trend of the same period last year. Such outstanding achievements are inseparable from the outstanding contribution of its core products and the efficient promotion of market expansion. The core product Obtunib continued to perform well, with sales revenue increasing by 89.2% year-on-year to RMB 310 million, becoming the core engine of performance growth. After its three major indications, especially marginal zone lymphoma, were included in ...
- Source: drugdu
- 45
- May 19, 2025
The world’s largest superconducting magnet machinery company is aiming for an IPO

Recently, according to the official website of the Shanghai Stock Exchange, the IPO application of Ningbo Jianxin Superconducting Technology Co., Ltd. (hereinafter referred to as Jianxin Superconducting) on the Science and Technology Innovation Board has been accepted. It is worth mentioning that the company has become the third company to be accepted on the Science and Technology Innovation Board in 2025. According to the prospectus, Jianxin Superconducting is mainly engaged in the research and development, production and sales of core components of medical magnetic resonance imaging (MRI) equipment. The company was founded in 2013. After years of development in the MRI industry, its main products are now widely deployed in the MRI field, including superconducting magnets, permanent magnets and gradient coils. In addition, Jianxin Superconducting has mastered a number of core technologies in the MRI field and is committed to implementing the technology. It is worth mentioning that Jianxin Superconducting ...
- Source: drugdu
- 40
- May 19, 2025
Wearable defibrillator patch is approved

Recently, Element Science announced that its wearable defibrillator patch has been approved by the U.S. Food and Drug Administration (FDA) after being approved by British and European regulators early last year. This non-invasive device provides an innovative solution for patients with a temporarily increased risk of cardiac arrest. It is reported that the device is suitable for patients recovering from heart attacks and other patients with serious cardiovascular diseases. The Jewel Patch-WCD wearable cardioverter defibrillator system adopts a lightweight and waterproof design, which supports continuous wear during sleep and showering. The system includes a reusable defibrillator device, a battery pack, and a disposable electrode patch that is replaced once a week. Uday Kumar, President and CEO of Element Science, said that the Jewel patch-type external defibrillator has realized the vision of seamlessly integrating life-saving equipment into patients’ daily lives. This FDA approval not only means the achievement of a regulatory ...
- Source: drugdu
- 36
- May 19, 2025
Discovery of mutated immune cell clones could point to improved treatment for refractory celiac disease

Scientists have identified mutated immune cell clones that could point to improved treatment for refractory celiac disease. Researchers at the Garvan Institute of Medical Research and UNSW Sydney have discovered why some people with celiac disease continue to suffer debilitating symptoms despite strictly avoiding gluten. The study, published in Science Translational Medicine, used cutting-edge single-cell sequencing techniques to reveal that certain immune cells in the gut of these patients carry genetic mutations. The team’s findings suggest these abnormal immune cells are driving ongoing intestinal inflammation that causes symptoms like diarrhoea, pain and malnutrition – pointing to a new way to diagnose and potentially treat the most severe form of celiac disease. Rogue immune cells emerge as hidden culprits celiac disease is a chronic autoimmune condition where the body mistakenly attacks the small intestine in response to gluten, a protein found in wheat, barley and rye. While most people with ...
- Source: drugdu
- 39
- May 19, 2025
HHS, FDA Begin ‘Operation Stork Speed’ to Improve Quality of Infant Formula

The U.S. Department of Health and Human Services and U.S. Food and Drug Administration have begun to comprehensively review the nutritional value of infant formula, a program the agencies have dubbed Operation Stork Speed. Operation Stork Speed aims to review the nutrient content of infant formula, increase testing for heavy metals and contaminants, encourage companies to develop new formulas, and clarify ways to better inform consumers about formula ingredients. Individual nutrient requirements for infant formula are already reviewed at regular intervals; however, this will be the first comprehensive review since 1998. The FDA has initiated Operation Stork Speed with a Request for Information (RFI) to gather public input. This input will be used to evaluate whether current nutrient requirements need to be updated based on the most recent scientific findings, including international data. The agency is also interested in receiving input regarding potential adjustments to the current minimum or maximum ...
- Source: drugdu
- 37
- May 19, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.